⬇️ 下载 PDF
红蓝生物

🧬 抗人B7-H3参考抗体

Anti-Human B7-H3 Reference Antibody

货号: RB9T37015038
💡 在您使用本产品前请认真阅读说明书,这对您顺利完成实验很有帮助。
🏷️ 产品编码
RB9T37015038
🧬 中文名称
抗人B7-H3参考抗体
📝 英文名称
Anti-Human B7-H3 Reference Antibody
📦 形态
Liquid
🧪 纯度
>95% purity as determined by SDS-PAGE.
🔹 内毒素水平
Please contact the lab for this information.
🔬 应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
🧫 表达系统
Mammalian Cells
🔢 登录号
Q5ZPR3
🔹 宿主种属
Humanized
🔹 克隆性
Monoclonal
🔹 抗体亚型
IgG1-kappa
🔹 纯化方式
Protein A/G purified from cell culture supernatant.
🔹 浓度
1mg/ml
🔹 种属反应性
Human
🔹 靶标
CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen
🔹 背景信息
Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.
🏷️ 别名
ABBV-155, 2229859-11-2
🧴 储存缓冲液
0.01M PBS, pH 7.4.
❄️ 稳定性和储存
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
⚠️ For research use only. Not suitable for clinical or therapeutic use.